BIO SOLUTION CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18,510 KRW | -6.84% |
|
-5.46% | -4.54% |
| Sales 2019 | 8.88B 6.46M 538M | Sales 2020 | 7.74B 5.63M 469M | Capitalization | 235B 171M 14.22B |
|---|---|---|---|---|---|
| Net income 2019 | -698M -507K -42.28M | Net income 2020 | -1.8B -1.31M -109M | EV / Sales 2019 | 34 x |
| Net cash position 2019 | 39.72B 28.88M 2.41B | Net cash position 2020 | 34.77B 25.28M 2.11B | EV / Sales 2020 | 25.8 x |
| P/E ratio 2019 |
-485
x | P/E ratio 2020 |
-130
x | Employees | 71 |
| Yield 2019 * |
-
| Yield 2020 |
-
| Free-Float | 79.81% |
More Fundamentals
* Assessed data
More news
| 1 day | -6.84% | ||
| 1 week | -5.46% | ||
| Current month | +7.43% | ||
| 1 month | +1.15% | ||
| 3 months | +10.38% | ||
| 6 months | +59.98% | ||
| Current year | -4.54% |
1 week
18 360.00
23 250.00
1 month
16 000.0023 250.00
Current year
14 960.0023 250.00
1 year
9 210.0024 050.00
3 years
9 210.0032 950.00
5 years
9 210.0050 900.00
10 years
9 210.0072 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
Song-Sun Chang
CEO | Chief Executive Officer | 67 | - |
Ji-Wook Jeong
DFI | Director of Finance/CFO | 56 | - |
Jung-Sun Lee
CTO | Chief Tech/Sci/R&D Officer | 52 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Song-Sun Chang
CEO | Chief Executive Officer | 67 | - |
Jae-Soon Park
BRD | Director/Board Member | 68 | - |
Nam-Moon Kim
BRD | Director/Board Member | 72 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 18,510 | -6.84% | 101,163 |
| 25/24/25 | 19,870 | -7.37% | 125,189 |
| 24/24/24 | 21,450 | -2.50% | 94,024 |
| 23/24/23 | 22,000 | -1.12% | 204,253 |
| 22/24/22 | 22,250 | +13.64% | 406,976 |
End-of-day quote Korea S.E., April 26, 2024
More quotes
Bio Solution Co.,Ltd. is a Korea based company mainly engaged in the manufacturing and distribution of cell therapy products. The Company manufactures and sells cell based cosmetic raw materials and therapeutics with background in somatic and stem cell technology. The Companyâs major products include cosmetic raw material called stem water, which contains human stem cells has whitening and anti-wrinkling effects; as well as keratinocyte medication for severe burns and chondrocyte therapy product used to cure arthritis. The Company also researches and develops human tissue models for toxicity and efficacy testing using tissue engineering technology.
Sector
Pharmaceuticals
Calendar
13/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -4.54% | 108M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
- Stock Market
- Equities
- A086820 Stock
